LON:MXCT MaxCyte (MXCT) Share Price, News & Analysis GBX 1.12 -0.02 (-1.75%) As of 07/23/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider TradesBuy This Stock About MaxCyte Stock (LON:MXCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MaxCyte alerts:Sign Up Key Stats Today's Range 1.09▼ 1.1450-Day Range 1▼ 1.4252-Week Range 147.69▼ 407.84Volume533,404 shsAverage Volume42,065 shsMarket Capitalization£1.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients. For over 20 years, MaxCyte has been perfecting the art of cell-engineering, venturing beyond today’s process to innovate tomorrow’s solutions. Let’s Build Better Cells Together. To learn more, please visit www.maxcyte.com Read More Receive MXCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MXCT Stock News HeadlinesCraig-Hallum Reaffirms Their Buy Rating on MaxCyte (MXCT)June 19, 2026 | theglobeandmail.comMaxCyte Shareholders Reelect Directors and Ratify AuditorJune 17, 2026 | tipranks.comElon did WHAT?!Something big is happening beyond SpaceX. Accelerated AI stocks have surged 133%, 217%, and even 320% in just a few months, according to Jason Bodner, founder of Inflection Point. Bodner says the trend hasn't caught mainstream attention yet, even as the technology behind it drives rapid gains for early investors.July 26 at 1:00 AM | Brownstone Research (Ad)MaxCyte Inc (MXCT) Q1 2026 Earnings Call Highlights: Revenue Meets Expectations Amid Core ...May 13, 2026 | finance.yahoo.comMaxCyte Faces Nasdaq Delisting Risk as Share Price Slump Threatens Liquidity and Capital AccessMarch 27, 2026 | tipranks.comMaxCyte Appoints Parmeet Ahuja as Chief Financial OfficerMarch 23, 2026 | markets.businessinsider.comMaxCyte Faces Nasdaq Noncompliance Over Minimum Bid PriceMarch 20, 2026 | tipranks.comMaxCyte (MXCT) Launches ExPERT DTx Platform to Accelerate High-Throughput Drug DiscoveryFebruary 25, 2026 | finance.yahoo.comSee More Headlines MXCT Stock Analysis - Frequently Asked Questions How have MXCT shares performed this year? MaxCyte's stock was trading at GBX 1.58 at the beginning of 2026. Since then, MXCT stock has decreased by 29.1% and is now trading at GBX 1.12. How do I buy shares of MaxCyte? Shares of MXCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of MaxCyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that MaxCyte investors own include HSBC (HSBA), EQTEC (EQT), Grafton Group (GFTU), Lloyds Banking Group (LLOY) and Marks and Spencer Group (MKS). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Medical Devices Sub-IndustryBusiness Services Current SymbolLON:MXCT CIKN/A Webwww.maxcyte.com Phone+1-301-9441700FaxN/AEmployees80Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£45.08 million Net Margins-119.69% Pretax MarginN/A Return on Equity-11.59% Return on Assets-11.07% Debt Debt-to-Equity Ratio9.70 Current Ratio12.39 Quick Ratio14.38 Sales & Book Value Annual Sales£32.29 million Price / Sales0.04 Cash FlowGBX 0.57 per share Price / Cash Flow1.97 Book ValueGBX 203.85 per share Price / Book0.01Miscellaneous Outstanding Shares106,319,000Free FloatN/AMarket Cap£1.19 million OptionableNot Optionable Beta1.13 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (LON:MXCT) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThis tiny piece of glass could be bigger than GPUsJensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...Brownstone Research | SponsoredThe 90%-off options that empty accountsA call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...Profits Run | SponsoredHave you seen Elon’s new “supercurrency”? (It affects you)Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access t...StocksToTrade | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MXCT Stock Alerts